GT Biopharma - GTBP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $150.00
  • Forecasted Upside: 3,976.09%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.68
▼ -0.22 (-5.64%)

This chart shows the closing price for GTBP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GT Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GTBP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GTBP

Analyst Price Target is $150.00
▲ +3,976.09% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for GT Biopharma in the last 3 months. The average price target is $150.00, with a high forecast of $150.00 and a low forecast of $150.00. The average price target represents a 3,976.09% upside from the last price of $3.68.

This chart shows the closing price for GTBP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in GT Biopharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$150.00Low
4/3/2023HC WainwrightReiterated RatingBuy$150.00Low
3/31/2023EF Hutton Acquisition Co. IReiterated RatingHold$60.00N/A
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageHold$60.00Low
9/13/2022HC WainwrightLower TargetBuy$750.00 ➝ $150.00Low
8/11/2022Roth CapitalDowngradeBuy ➝ NeutralLow
1/24/2022B. RileyLower Target$780.00 ➝ $540.00High
11/15/2021HC WainwrightReiterated RatingBuy$720.00Low
9/14/2021HC WainwrightReiterated RatingBuy$750.00Medium
6/28/2021HC WainwrightReiterated RatingBuy$750.00High
6/24/2021B. RileyReiterated RatingBuy$630.00 ➝ $780.00High
5/24/2021HC WainwrightInitiated CoverageBuy$750.00Medium
4/13/2021B. RileyInitiated CoverageBuy$630.00Medium
3/17/2021Roth CapitalInitiated CoverageBuy$750.00High
(Data available from 5/27/2019 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/27/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2024

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

GT Biopharma logo
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
Read More

Today's Range

Now: $3.68
Low: $3.56
High: $4.09

50 Day Range

MA: $3.94
Low: $3.00
High: $7.80

52 Week Range

Now: $3.68
Low: $2.95
High: $16.11

Volume

147,900 shs

Average Volume

861,924 shs

Market Capitalization

$5.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Frequently Asked Questions

What sell-side analysts currently cover shares of GT Biopharma?

The following Wall Street sell-side analysts have issued reports on GT Biopharma in the last year: HC Wainwright.
View the latest analyst ratings for GTBP.

What is the current price target for GT Biopharma?

1 Wall Street analysts have set twelve-month price targets for GT Biopharma in the last year. Their average twelve-month price target is $150.00, suggesting a possible upside of 3,976.1%. HC Wainwright has the highest price target set, predicting GTBP will reach $150.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $150.00 for GT Biopharma in the next year.
View the latest price targets for GTBP.

What is the current consensus analyst rating for GT Biopharma?

GT Biopharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GTBP will outperform the market and that investors should add to their positions of GT Biopharma.
View the latest ratings for GTBP.

What other companies compete with GT Biopharma?

How do I contact GT Biopharma's investor relations team?

GT Biopharma's physical mailing address is 9350 Wilshire Blvd. Suite 203, Beverly Hills CA, 90212. The company's listed phone number is (415) 919-4040 and its investor relations email address is [email protected]. The official website for GT Biopharma is www.gtbiopharma.com. Learn More about contacing GT Biopharma investor relations.